Real-time SEC alerts Start Free →
Profitelligence
Danaher Corporation
DHR HIGH Impact

Danaher Corporation

Danaher Reports 2025 Financial Results and Provides 2026 Guidance

| 8-K |Healthcare

Summary

Danaher Corporation announced its 2025 financial results, reporting net earnings of $3.6 billion, or $5.03 per diluted share. The company saw revenue increase by 3% to $24.6 billion, with non-GAAP core revenue rising by 2%. Operating cash flow was $6.4 billion, and free cash flow was $5.3 billion. For 2026, Danaher anticipates non-GAAP core revenue growth in the range of 3% to 6% and adjusted diluted net earnings per share between $8.35 and $8.50. The company also adjusted its financial measures to exclude certain items to better reflect underlying performance.

Profitelligence Profitelligence Alerts

Get alerts for DHR

Be first to know when Danaher Corporation files with the SEC.

Set Up Alerts →

Filing Categories

General Statement Earnings Beat Raised Guidance

Advertisement

About Danaher Corporation

Danaher Corporation is a globally recognized science and technology company specializing in the development, design, and manufacturing of diverse industrial and healthcare products. With a primary focus on innovations in diagnostics, life sciences, dental, and environmental and applied solutions, Danaher serves a multitude of industries and market sectors. Its cutting-edge diagnostic equipment aids medical professionals in delivering precise healthcare, while its life sciences tools and technologies propel biomedical research and development. The company's environmental solutions also play a key role in enhancing water quality analysis and management. Headquartered in Washington, D.C., Danaher is renowned for its strong operational culture exemplified by the Danaher Business System (DBS), which emphasizes continuous improvement and sustainable innovation. This approach has solidified Danaher's presence and influence in both developing specialized solutions and improving efficiency across global markets. The company's strategic acquisitions and consistent focus on innovation have positioned it as a leader in delivering essential solutions that drive significant improvements for healthcare, research, and industrial clients.

Exchange: NYSE Industry: Diagnostics & Research Company Website →

Official SEC Documents

DHR
DHR Research
8Ks, insider trades, financials, technicals
SEC Alert Manager
Get alerts within 60 seconds of new filings

Advertisement